RE-DUAL TICLO PCI: Dual Therapy with dabigatran/ticagrelor versus Dual Therapy with dabigatran/clopidogrel in ACS patients with indication for NOAC undergoing PCI.

Status

Completed

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518666-27-00

Enrollment

1000

Registered

2024-11-25

Start date

Unknown

Completion date

2025-05-07

Last updated

2024-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome

Brief summary

The primary endpoint is the first bleeding event (major and clinically relevant non-major), as defined by the Bleeding Academic Research Council (BARC) score ≥2 after 12 months follow-up (12).

Detailed description

The secondary endpoints are efficacy endpoints of thromboembolic events (myocardial infarction, stroke, systemic embolism) and death. Other secondary endpoints are a composite endpoint of thromboembolic events or death, as well as the individual thromboembolic events and stent thrombosis.

Interventions

DRUGTICAGRELOR

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the first bleeding event (major and clinically relevant non-major), as defined by the Bleeding Academic Research Council (BARC) score ≥2 after 12 months follow-up (12).	—

Secondary

Measure	Time frame
The secondary endpoints are efficacy endpoints of thromboembolic events (myocardial infarction, stroke, systemic embolism) and death. Other secondary endpoints are a composite endpoint of thromboembolic events or death, as well as the individual thromboembolic events and stent thrombosis.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026